Sam Klempner, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment strategies for esophageal, GE junction, and gastric cancers.
Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer
Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
ASCO Guideline Issues Updated Systemic Therapy Recommendations in HCC
Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.